Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04203563
Other study ID # MG071019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 20, 2019
Est. completion date December 23, 2019

Study information

Verified date July 2020
Source Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Strong People Strength Training study aims to assess whether a community-based progressive strength training program can improve risk factors for diabetes and heart disease in older rural adults.


Description:

This study aims to evaluate the effects of a twice weekly, 12-week progressive strength training program, Strong People Strength Training, on cardiometabolic risk factors in a pragmatic, community-based randomized intervention trial among rural men and women 50 and older. We hypothesize that individuals randomized to the intervention group will demonstrate statistically significant and clinically meaningful improvements in cardiometabolic risk factors as well as physical function, quality of life, and physical activity compared to those randomized to the delayed intervention control group.


Recruitment information / eligibility

Status Completed
Enrollment 167
Est. completion date December 23, 2019
Est. primary completion date December 23, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 100 Years
Eligibility Inclusion Criteria:

- Age 50 or older

- Willing and able to get health care provider (HCP) authorization if required (PAR-Q answered yes to any question or 70 and older)

Exclusion Criteria:

- Strength trained in last 12 months

- Previous enrollment in Strong People

- Enrolled or planning to enroll in lifestyle program

- Cognitive impairment

- Unable to obtain physician authorization

Study Design


Intervention

Behavioral:
Strong People Strength Training
A community-based progressive strength training program

Locations

Country Name City State
United States Teton County Choteau Montana
United States Chouteau County Fort Benton Montana
United States Valley County Glasgow Montana
United States Big Horn County Hardin Montana
United States Hill County Havre Montana
United States Wibaux County Wibaux Montana

Sponsors (3)

Lead Sponsor Collaborator
Cornell University Montana State University, Texas A&M University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Hemoglobin A1c at 12 Weeks The hemoglobin A1c test tells you your average level of blood sugar over the past 2 to 3 months. It's also called HbA1c. Baseline and outcome (after 12 weeks)
Primary Change from Baseline BMI at 12 Weeks Body mass index (BMI) is a measure of body fat based on height and weight that applies to adult men and women. Baseline and outcome (after 12 weeks)
Primary Change from Baseline Weight at 12 Weeks body weight Baseline and outcome (after 12 weeks)
Primary Change from Baseline in American Heart Association's Life's Simple 7 score at 12 Weeks The American Heart Association's Life's Simple 7 score is comprised of seven cardiovascular disease (CVD) risk factors: physical activity, healthy diet score, blood glucose, BMI, blood cholesterol, blood pressure, and smoking; each risk factor is categorized as ideal, intermediate, or poor.
Minimum value is 0, Maximum value is 14. Higher scores on the scale represent a better outcome.
Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Cholesterol at 12 Weeks Total cholesterol measured with the Alere Cholestech LDX Analyzer Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Resting Heart Rate at 12 Weeks Heart rate (beats per minute) while at rest Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Blood Pressure at 12 Weeks Blood pressure measured at rest; systolic over diastolic (mm Hg) Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Functional Fitness Tests at 12 Weeks Six domains of the functional fitness/ senior fitness tests Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Physical Activity at 12 Weeks measured using accelerometry Objective physical activity measured using an accelerometer worn for 7 days Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Physical Activity at 12 Weeks measured using self-report Self-report physical activity measured using CHAMPS Activities Questionnaire for Older Adults.
Questionnaire includes 41 activity questions and participant reports on number of hours per week involved in each activity using possible responses: less than 1 hour; 1-2.5 hours; 3-4.5 hours; 5-6.5 hours; 7-8.5 hours; 9 or more hours. More hours reported corresponds with more time in physical activity.
Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Fatigue at 12 Weeks Measured with self report using the Visual Analogue Scale to Evaluate Fatigue Severity (VAS-F). This validated scale consists of 18 items relating to the experience of fatigue. Each item the participant responds on a scale of 0 to 10. For example with 0 being not at all tired and 10 being extremely tired. Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Depression using the Center for Epidemiologic Studies Depression Scale (CES-D) at 12 Weeks Measured with self report using the Center for Epidemiologic Studies Depression Scale (CES-D). Score ranges from 0 to 60 with with higher scores indicating the presence of more depression symptoms. Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Depression using the Patient Health Questionnaire (PHQ-8) at 12 Weeks Measured with self report using the Patient Health Questionnaire (PHQ-8). Score ranges from 0 to 24 with greater scores reflecting more depression symptoms. Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Anxiety at 12 Weeks using the Beck Anxiety Inventory Anxiety measured by questionnaire using the Beck Anxiety Inventory which is a 21-question multiple-choice self-report inventory that is used for measuring the severity of anxiety. Scores range from 0 to 63 with higher scores indicating more anxiety. Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Anxiety at 12 Weeks using the the General Anxiety Disorder Scale (GAD-7) Anxiety measured by questionnaire using the General Anxiety Disorder Scale (GAD-7) which consists of 7 questions with responses from Not at all, Several Days, More than half hte days, and Nearly every day. Scores range from 0 to 21 with higher scores reflecting more anxiety. Baseline and outcome (after 12 weeks)
Secondary Change from Baseline Stress at 12 Weeks Measured with self report using the Perceived Stress Scale (PSS). Scores range from 0 to 40 with higher scores reflecting more perceived stress. Baseline and outcome (after 12 weeks)
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4